With regards to your comment: " Ok, so we know the Crestor (rosuvastatin) group did better than the Lipitor (atorvastatin) group in plaque regression and reverse cholesterol transport."
-BOM did not conduct Intravascular ultrasound (IVUS) medical imaging. Therefore we will not know any more than was done in the ASSURE trial with regards to plaque regression and reverse cholesterol transport.
-The post hoc analysis from the pooled SUSTAIN and ASSURE clinical trials produced a 77% RRR of MACE in patients with DM for the entire group of patients. So there was no analysis conducted that separated the two statins vs placebo.
Based on the above basis, how can Resverlogix take advantage of the patent, (the combination of rosuvastatin and ABL) with the BOM trial?
Koo
